The up-regulation of BCL2A1 was identified as one of the key mechanisms of BH3-mimetic drug resistance in CLL cells receiving these signals from fibroblast feeder layers and cytokines in vitro [48]. The gene discussed is BCL2A1; the disease is B-cell chronic lymphocytic leukemia.